The respiratory syncytial virus (RSV) is a human pathogen that causes a lower respiratory infection in infants and healthy adults. The first incidence of RSV was recorded in the 1960s. The greatest success against viruses has always been by increasing immunity through vaccination like in smallpox, measles, influenza, polio. Though RSV spread its roots almost six decades ago, the creation of a vaccine against RSV is still an ongoing challenge. The structural proteins of RSV, mainly F and G, play an essential role in pathogenicity. Structural instability of the F protein is responsible for making the vaccine discovery an uncertain outcome. This review focuses on the details of the vaccine strategies that have been explored so far. It includes an emphasis on the initial formalin-inactivated vaccine, structure-based vaccine, monoclonal antibodies like Palivizumab with a concise portrayal of nanoparticle, chimeric vaccines, and maternal derived immunization. The structure-based vaccine is one of the most reliable strategies to explicate further research. Focusing on the epitopes that monoclonal antibodies can act upon will result in dependable vaccine outcomes.